secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moderna, Inc. (MRNA)
CIK:        0001682852
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0001682852-24-000004
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Moderna reports preliminary 2023 product sales ~$6.7B; guides 2024 sales ~$4B, targets break-even 2026
--------------------------------------------------------------------------------

- 2023 COVID-19 vaccine product sales ~$6.7B (incl. $0.6B deferred revenue from GAVI).
- Cash, cash equivalents & investments >$13B at Dec 31, 2023.
- 2024 product sales guidance ~$4B, mostly H2; targets break-even by 2026.
- RSV vaccine regulatory filings submitted; expects approvals beginning H1 2024.
- U.S. COVID-19 market share season-to-date 48% (up from 37% in 2022).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1682852/000168285224000004/0001682852-24-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1682852/000168285224000004/mrna-20240108.htm
  HTML page:      https://secwatch.observer/filing/0001682852-24-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer